167 related articles for article (PubMed ID: 38115002)
41. Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia.
Assefa A; Mohammed H; Anand A; Abera A; Sime H; Minta AA; Tadesse M; Tadesse Y; Girma S; Bekele W; Etana K; Alemayehu BH; Teka H; Dilu D; Haile M; Solomon H; Moriarty LF; Zhou Z; Svigel SS; Ezema B; Tasew G; Woyessa A; Hwang J; Murphy M
Malar J; 2022 Dec; 21(1):359. PubMed ID: 36451216
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Papua New Guinea.
Tavul L; Hetzel MW; Teliki A; Walsh D; Kiniboro B; Rare L; Pulford J; Siba PM; Karl S; Makita L; Robinson L; Kattenberg JH; Laman M; Oswyn G; Mueller I
Malar J; 2018 Oct; 17(1):350. PubMed ID: 30290825
[TBL] [Abstract][Full Text] [Related]
43. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.
Ratcliff A; Siswantoro H; Kenangalem E; Maristela R; Wuwung RM; Laihad F; Ebsworth EP; Anstey NM; Tjitra E; Price RN
Lancet; 2007 Mar; 369(9563):757-765. PubMed ID: 17336652
[TBL] [Abstract][Full Text] [Related]
44. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
Milligan R; Daher A; Villanueva G; Bergman H; Graves PM
Cochrane Database Syst Rev; 2020 Aug; 8():CD012656. PubMed ID: 32816320
[TBL] [Abstract][Full Text] [Related]
45. Prevalence of mutations in the cysteine desulfurase IscS (Pfnfs1) gene in recurrent Plasmodium falciparum infections following artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) treatment in Matayos, Western Kenya.
Gachie B; Thiong'o K; Muriithi B; Chepngetich J; Onchieku N; Gathirwa J; Mwitari P; Magoma G; Kiboi D; Kimani F
Malar J; 2023 May; 22(1):158. PubMed ID: 37202779
[TBL] [Abstract][Full Text] [Related]
46. Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination.
Gerardin J; Eckhoff P; Wenger EA
BMC Infect Dis; 2015 Mar; 15():144. PubMed ID: 25887935
[TBL] [Abstract][Full Text] [Related]
47. Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria.
Blanshard A; Hine P
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD004529. PubMed ID: 33459345
[TBL] [Abstract][Full Text] [Related]
48. Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission.
Graves PM; Choi L; Gelband H; Garner P
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD008152. PubMed ID: 29393511
[TBL] [Abstract][Full Text] [Related]
49. Factors affecting haemoglobin dynamics in African children with acute uncomplicated Plasmodium falciparum malaria treated with single low-dose primaquine or placebo.
Onyamboko MA; Olupot-Olupot P; Were W; Namayanja C; Onyas P; Titin H; Baseke J; Muhindo R; Kayembe DK; Ndjowo PO; Basara BB; Okalebo CB; Williams TN; Uyoga S; Taya C; Bamisaiye A; Fanello C; Maitland K; Day NPJ; Taylor WRJ; Mukaka M
BMC Med; 2023 Oct; 21(1):397. PubMed ID: 37858129
[TBL] [Abstract][Full Text] [Related]
50. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age.
Betuela I; Rosanas-Urgell A; Kiniboro B; Stanisic DI; Samol L; de Lazzari E; Del Portillo HA; Siba P; Alonso PL; Bassat Q; Mueller I
J Infect Dis; 2012 Dec; 206(11):1771-80. PubMed ID: 22966124
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine.
Daher A; Aljayyoussi G; Pereira D; Lacerda MVG; Alexandre MAA; Nascimento CT; Alves JC; da Fonseca LB; da Silva DMD; Pinto DP; Rodrigues DF; Silvino ACR; de Sousa TN; de Brito CFA; Ter Kuile FO; Lalloo DG
Malar J; 2019 Sep; 18(1):325. PubMed ID: 31547827
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of pyronaridine-artesunate (PYRAMAX) for the treatment of
Djimde M; Tshiongo JK; Muhindo HM; Tinto H; Sevene E; Traore M; Vala A; Macuacua S; Kabore B; Dabira ED; Erhart A; Diakite H; Keita M; Piqueras M; González R; Menendez C; Dorlo TP; Sagara I; Mens P; Schallig H; D'Alessandro U; Kayentao K
BMJ Open; 2023 Oct; 13(10):e065295. PubMed ID: 37813539
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in four malaria endemic states of India.
Krishna S; Mishra S; Tiwari P; Vishwakarma AK; Khandai S; Shrivastava S; Verma AK; Tiwari S; Barman H; Jhariya S; Tiwari P; Tidgam AS; Varun BM; Singh S; Yerane N; Tembhurne CR; Mandavi PL; Tekam SS; Malik M; Behera KP; Jayswar H; Sonwani K; Diggikar MS; Pradhan MM; Khasotiya SS; Kumar A; Dhingra N; Bustos MDG; Christophel EM; Ringwald P; Kumari R; Shukla MM; Singh N; Das A; Bharti PK
Malar J; 2021 May; 20(1):229. PubMed ID: 34020652
[TBL] [Abstract][Full Text] [Related]
54. Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.
Hamaluba M; van der Pluijm RW; Weya J; Njuguna P; Ngama M; Kalume P; Mwambingu G; Ngetsa C; Wambua J; Boga M; Mturi N; Lal AA; Khuroo A; Taylor WRJ; Gonçalves S; Miotto O; Dhorda M; Mutinda B; Mukaka M; Waithira N; Hoglund RM; Imwong M; Tarning J; Day NPJ; White NJ; Bejon P; Dondorp AM
Lancet Infect Dis; 2021 Oct; 21(10):1395-1406. PubMed ID: 34111412
[TBL] [Abstract][Full Text] [Related]
55. Adding a single low-dose of primaquine (0.25 mg/kg) to artemether-lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single-blinded clinical trial.
Mwaiswelo R; Ngasala B; Jovel I; Aydin-Schmidt B; Gosling R; Premji Z; Mmbando B; Björkman A; Mårtensson A
Malar J; 2016 Aug; 15(1):435. PubMed ID: 27565897
[TBL] [Abstract][Full Text] [Related]
56. Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults.
Healy SA; Murphy SC; Hume JCC; Shelton L; Kuntz S; Van Voorhis WC; Moodie Z; Metch B; Wang R; Silver-Brace T; Fishbaugher M; Kennedy M; Finney OC; Chaturvedi R; Marcsisin SR; Hobbs CV; Warner-Lubin M; Talley AK; Wong-Madden S; Stuart K; Wald A; Kappe SH; Kublin JG; Duffy PE
Clin Infect Dis; 2020 Sep; 71(6):1481-1490. PubMed ID: 31621832
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial.
Banda CG; Chaponda M; Mukaka M; Mulenga M; Hachizovu S; Kabuya JB; Mulenga J; Sikalima J; Kalilani-Phiri L; Terlouw DJ; Khoo SH; Lalloo DG; Mwapasa V
Malar J; 2019 May; 18(1):180. PubMed ID: 31126288
[TBL] [Abstract][Full Text] [Related]
58. The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria.
Bassat Q
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1325. PubMed ID: 22216359
[TBL] [Abstract][Full Text] [Related]
59. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria.
Zani B; Gathu M; Donegan S; Olliaro PL; Sinclair D
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD010927. PubMed ID: 24443033
[TBL] [Abstract][Full Text] [Related]
60. [A Marginal Case of Malaria: An Interesting Malaria Story of Cameroon Origin].
Erdoğan E; Türe Yüce Z; Ayrık Demir A; Yaman O; Yürük M; Yıldız O
Mikrobiyol Bul; 2023 Jul; 57(3):498-505. PubMed ID: 37462313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
